First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing

Cinzia Dello Russo, Pierluigi Navarra, Genny Meini, Tiziano Allice, Renata Barresi, Roberta D'Arrigo, Francesca Falasca, Maria Rosaria Lipsi, Stefania Paolucci, Stefania Zanussi, Raffaele Antonetti, Fausto Baldanti, Giancarlo Basaglia, Bianca Bruzzone, Ennio Polilli, Valeria Ghisetti, Leopoldo Paolo Pucillo, Ombretta Turriziani, Antonella Pirazzoli, Maurizio Zazzi

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

4 Citazioni (Scopus)

Abstract

BACKGROUND: Since the HLA-B*57:01 allele is strongly associated with abacavir hypersensitivity reaction, testing for the presence of HLA-B*57:01 is mandatory before administration of abacavir. While HLA-B*57:01 testing is usually provided by pharmacogenetics, genetics or blood transfusion services, clinical virology laboratories can be an optimal opportunity for HLA-B*57:01 testing since they receive blood samples for routine HIV monitoring and have the expertise for convenient and less expensive PCR-based point mutation assays. OBJECTIVES: The Italian HLA-B*57:01 Network gathers accredited clinical virology laboratories offering HLA-B*57:01 testing in Italy with the aim to share protocols, test new methods, develop and maintain external quality assurance (EQA) programs. STUDY DESIGN: A panel of 9HLA-B*57:01-positive and 16HLA-B*57:01-negative frozen blood samples were blindly distributed to 10 units including 9 clinical virology laboratories and one reference pharmacology laboratory. Each laboratory was free to use its own routine method for DNA extraction and HLA-B*57:01 testing. RESULTS: DNA was extracted by automated workstations in 6 units and by manual spin columns in 4. Eight units used the Duplicα Real Time HLA-B*57:01 kit by Euroclone and two units used two different PCR homemade protocols. All the 10 units correctly identified all the 25 samples. CONCLUSIONS: The first HLA-B*57:01 EQA program run in Italy showed that clinical virology units are equipped and proficient for providing HLA-B*57:01 testing by inexpensive assays easy to integrate into their routine.
Lingua originaleEnglish
pagine (da-a)1-3
Numero di pagine3
RivistaJournal of Clinical Virology
Volume78
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Abacavir hypersensitivity reaction
  • External quality assurance
  • HIV
  • HLA-B*57:01 testing

Fingerprint Entra nei temi di ricerca di 'First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing'. Insieme formano una fingerprint unica.

Cita questo